{"companyId":359626,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","ja"],"companyName":"Samsung Epis Holdings Co., Ltd.","headOfficeLocation":"Incheon, South Korea","presidentName":"Kyung-Ah Kim","companySummary":null,"stockCode":"0126Z0","currency":"KRW","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["samsungepisholdings.com"],"businessContents":["Biopharmaceutical investment holding company"],"relations":[{"detailNumber":1,"relationCompanyName":"Samsung Bioepis Co., Ltd.","relationCompanyId":380453,"url":"https://www.businesswire.com/news/home/20251030908044/en/Newly-Established-Samsung-Epis-Holdings-to-Drive-Growth-for-Samsung-Bioepis-and-a-New-Subsidiary","linkUrl":null,"remarks":"関連会社未登録","lastCheckDate":"2026-10-06","raGroup":70,"raParent":0,"raChild":0,"raCustomer":0,"raSupplier":0,"raPartnership":0,"raFinance":0,"raInvest":0}],"dataSources":[{"detailNumber":1,"url":"https://www.businesswire.com/news/home/20251030908044/en/Newly-Established-Samsung-Epis-Holdings-to-Drive-Growth-for-Samsung-Bioepis-and-a-New-Subsidiary","scoreAbout":100,"scoreBusiness":100,"scoreGroup":60,"scoreCustomer":0}]}